Cytyc ThinPrep Pap Test Distribution Helps Boost Stock 137% In 1999
This article was originally published in The Gray Sheet
Executive Summary
Increasing availability of Cytyc's ThinPrep Pap test product through added laboratory contracts, coupled with an improved reimbursement environment and strong fundamentals, set the stage for a 137.1% run up of the cervical cytology firm's stock in 1999. The issue closed at 61-1/16, up 35-5/16 for the year.
You may also be interested in...
Candela Gets Lift From Robust Economy, Demand For Aesthetic Procedures
Candela's stock price benefited from three related trends in 1999 - the increased acceptance of the company's flagship aesthetic lasers by physicians, an aging baby boom population willing to pay out-of-pocket for cosmetic surgical procedures, and a booming economy that has made prospective patients feel affluent enough not to give the expense a second thought.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.